Biosimilar developer Celltrion and Juno Pharmaceuticals announced that they have entered into a comarketing partnership for Celltrion’s trastuzumab biosimilar, Herzuma, and its rituximab biosimilar, Truxima, in the Australian market.
Biosimilar developer Celltrion and Juno Pharmaceuticals announced that they have entered into a comarketing partnership for Celltrion’s trastuzumab biosimilar, Herzuma, and its rituximab biosimilar, Truxima, in the Australian market.
Under the agreement, Celltrion will distribute the products in the Australian market, and Juno, a hospital supplier, will provide sales promotion and hospital contracting services to Australian hospital customers.
The new partnership comes shortly after Celltrion established its Australian branch in Sydney and subsequently joined Australia’s Generic and Biosimilar Medicines Association (GMBA), a group that represents generic and biosimilar manufacturers, suppliers, and exporters.
“At Celltrion Healthcare, our aim is to provide the best possible treatment options for patients and healthcare providers, and by connecting with the GBMA, we look forward to engaging positively to support the uptake of biosimilar medicines in Australia as a way to alleviate pressure on its national health system,” said Hyoung-Ki Kim, vice chairman and chief executive officer at Celltrion Healthcare, in a statement announcing the company’s new membership in the group.
The GBMA has taken an active role in providing education on biosimilars to stakeholders; in May of 2019, the group launched a new educational portal, funded by a grant by the Australian government, that provides tailored education to patients, prescribers, and pharmacists. Included in these materials is information on how some biosimilars—those that are “a-flagged”—can be substituted for their reference products at the point of dispensing.
Outside of Australia, Celltrion has been engaging in multiple other partnerships; in July of 2019, the company forged a joint venture, Vcell Healthcare Limited, together with Nan Fung Group to commercialize biosimilars in China. Last month, Celltrion also announced that it will contract with Swiss biologics maker Lonza to manufacture biosimilar infliximab CT-P13, sold as Remsima and Inflectra, in Singapore.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.